Highmark Health turns to Karen Hanlon as it confronts margin pressure and a larger scale of care
Highmark Health has named Karen Hanlon its next president and chief executive officer, placing a long-tenured insider at the helm as the integrated nonprofit system faces mounting strain in its insurance business and a broader need to protect financial stability. Hanlon will become the first woman to lead the organization when she takes over on Jan. 1. David Holmberg, who has served as chief executive since 2014, will move into the role of executive chairman and continue working closely with the company and board.
The succession lands at a sensitive moment for a system that derives more than 80% of its revenue from insurance operations. Highmark’s health plan business covers around 7 million people, and its operating loss of $609 million last year is a blunt reminder of how quickly utilization trends and medical costs can pressure even large nonprofit plans. In that setting, the choice of a chief executive with deep institutional experience carries obvious strategic weight. Hanlon has spent nearly three decades at Highmark, moving through finance and operational roles before becoming chief financial officer in 2014, then chief operating officer, and later president.
Her path to the top job also tells a larger story about how integrated health systems manage succession when the finance office and the operating room are tightly linked. Highmark is not a simple payer. It is a nonprofit system with an insurance arm and Allegheny Health Network, its western Pennsylvania health system, so the CEO must navigate two very different business pressures at once: keeping premiums, claims, and risk adjustment in balance while also supporting hospital and clinical operations. A leader who has spent years in finance and operations is often better positioned to see where one side of the enterprise is subsidizing, or burdening, the other.
Hanlon joined Highmark in 1997 after working at KPMG, and the company says she helped guide its growth from $17 billion in revenue in 2014 to a projected $35 billion in 2026. Growth at that scale can create its own strain. Larger revenue streams do not automatically produce better margins, especially when medical trend accelerates faster than premium pricing or when product adjustments lag behind shifting utilization. Highmark said its product changes should support a recovery this year, but the firm’s recent losses were severe enough to push S&P to lower its credit outlook from stable to negative earlier this year.
The change in outlook matters because credit ratings influence borrowing costs, capital flexibility, and the confidence of counterparties. For a nonprofit insurer and health system, those are not abstract finance metrics. They shape how aggressively the organization can invest in technology, contract with providers, support network strategy, and absorb another year of elevated claims expense. When a payer organization posts a large operating loss, the pressure extends beyond the finance department and into benefit design, provider contracting, and the day-to-day decisions that determine whether members keep affordable access to care.
Hanlon’s appointment also reflects the board’s long-term succession planning rather than an abrupt leadership correction. The company emphasized that she has earned trust across employees and stakeholders, language that points to a familiar challenge in large health organizations: the next chief executive must command both operational respect and financial credibility. In an integrated model, the CEO cannot focus only on one side of the ledger. Insurance losses can weaken the whole enterprise, while hospital performance can become vulnerable if the payer side fails to hold the line on costs. The job is to keep both sides functioning as one system rather than two competing businesses.
Her promotion follows an era in which the broader health plan sector has been squeezed by higher medical utilization, more expensive care, and tighter expectations from regulators, employers, and consumers. Highmark’s experience fits that pattern. The company’s health system arm improved its financial results last year and turned an operating profit for the first time since 2019, but that improvement was not enough to offset the stress in the insurance segment. In practical terms, the insurer’s performance is still carrying the greater weight inside the organization, and that imbalance will likely shape Hanlon’s early agenda.
One sentence captures the operating challenge ahead: the insurer’s losses remain too large to treat as a temporary wobble.
Hanlon now inherits a company with substantial reach, significant mission obligations, and a financial structure that demands disciplined execution. Her background in accounting, finance, operations, and enterprise leadership gives her a rare continuity advantage, but continuity is not the same as relief. The coming year will test whether Highmark can translate product changes into better margins, steady its insurance operations, and preserve the credit and capital standing needed to support both its plan members and its health system.
The leadership transition is scheduled, orderly, and internal. The financial demands around it are anything but.